LY-503,430
Prijeđi na navigaciju
Prijeđi na pretragu
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| 4'- {(1S)-1-fluoro-2-[(izopropilsulfonil)amino]-1-metiletil} -N-metilbifenil-4-karboksamid | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 625820-83-9 | ||
| ATC kod | nije dodeljen | ||
| ChemSpider[1] | 21212986 | ||
| Hemijski podaci | |||
| Formula | C20H25FN2O3S | ||
| Mol. masa | 392,49 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Sinonimi | LY-503,430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | Lek u razvoju | ||
| Način primene | oralno | ||
LY-503,430 je ampakinski lek koji je razvila kompanija Eli Lili.[2]
LY-503,430 proizvodi nootropne i neuroprotektivne efekte, čime redukuje moždana oštećenja uzrokovana 6-hidroksidopaminom ili MPTP-om. On isto tako povišava nivoe neurotrofnog faktora BDNF u mozgu, posebno u substantia nigra, hipokampusu i striatumu.[3][4] On je oralno aktivan. LY-503,430 se razvija za moguću primenu u lečenju Parkinsonove bolesti. Moguće je će naći primenu i u tretmanju Alchajmerove bolesti, depresije i šizofrenije.[5][6]
Reference[uredi | uredi kod]
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ O'neill, MJ; Murray, TK; Clay, MP; Lindstrom, T; Yang, CR; Nisenbaum, ES (2005). „LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease”. CNS Drug Reviews 11 (1): 77–96. DOI:10.1111/j.1527-3458.2005.tb00037.x. PMID 15867954.
- ↑ Murray, TK; Whalley, K; Robinson, CS; Ward, MA; Hicks, CA; Lodge, D; Vandergriff, JL; Baumbarger, P et al (2003). „LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 752–62. DOI:10.1124/jpet.103.049445. PMID 12730350.
- ↑ Ryder, JW; Falcone, JF; Manro, JR; Svensson, KA; Merchant, KM (2006). „Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors”. The Journal of Pharmacology and Experimental Therapeutics 319 (1): 293–8. DOI:10.1124/jpet.106.105734. PMID 16803862.
- ↑ O'neill, MJ; Bleakman, D; Zimmerman, DM; Nisenbaum, ES (2004). „AMPA receptor potentiators for the treatment of CNS disorders”. Current drug targets. CNS and neurological disorders 3 (3): 181–94. DOI:10.2174/1568007043337508. PMID 15180479.
- ↑ O'neill, MJ; Witkin, JM (2007). „AMPA receptor potentiators: application for depression and Parkinson's disease”. Current drug targets 8 (5): 603–20. DOI:10.2174/138945007780618517. PMID 17504104.
